
- /
- Supported exchanges
- / US
- / GLSI.NASDAQ
Greenwich Lifesciences Inc (GLSI NASDAQ) stock market data APIs
Greenwich Lifesciences Inc Financial Data Overview
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Greenwich Lifesciences Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Greenwich Lifesciences Inc data using free add-ons & libraries
Get Greenwich Lifesciences Inc Fundamental Data
Greenwich Lifesciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -18 137 912
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-11
- EPS/Forecast: -0.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Greenwich Lifesciences Inc News

Greenwich LifeSciences soars on FDA Fast Track status for lead asset
[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Greenwich LifeSciences (NASDAQ:GLSI [https://seekingalpha.com/symbol/GLSI]) added ~32% in the p...


Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, F...

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FL...

Greenwich LifeSciences brings clinical trial management in-house
STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a $165 million market cap biotechnology company currently trading at $12.01, announced Tuesday it is building an internal clinical trial m...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.